02/24/2024 18:26:28
Home | The deep dive for new drugs
In this issue
NSF
Contents
Hapa Company Insight
Daiichi Jitsugyo
News
Owen Mumford
The pharma industry briefing
Capsugel Company Insight
Swiss WorldCargo
In the age of AMR, does a nationalised drug company make sense? The case for and against
Accurate Biometrics Company Insight
Accurate Biometrics
Underwater forests and the search for natures’ next drug treasure trove
Barc Lab
BEA
Developing drugs for NASH: the race to market
SmartCAE Company Insight
SmartCAE
Zulresso: the world’s first post-partum depression drug
Ecocool
Moehs Iberica SL
Predicting drug flops with AI
Abiogen Pharma
Lauda
Proteomics and the promise of ‘enriching’ clinical trials
Lubrizol Life Sciences
Skycell
Events
Temptime
Next issue
Pfanstiehl Company Insight
Pfanstiehl
06/20/2019 00:00:00
Go to article:
Home | The deep dive for new drugs
Go to article:
In this issue
Go to article:
NSF
Go to article:
Contents
Go to article:
Hapa Company Insight
Go to article:
Daiichi Jitsugyo
Go to article:
News
Go to article:
Owen Mumford
Go to article:
The pharma industry briefing
Go to article:
Capsugel Company Insight
Go to article:
Swiss WorldCargo
Go to article:
In the age of AMR, does a nationalised drug company make sense? The case for and against
Go to article:
Accurate Biometrics Company Insight
Go to article:
Accurate Biometrics
Go to article:
Underwater forests and the search for natures’ next drug treasure trove
Go to article:
Barc Lab
Go to article:
BEA
Go to article:
Developing drugs for NASH: the race to market
Go to article:
SmartCAE Company Insight
Go to article:
SmartCAE
Go to article:
Zulresso: the world’s first post-partum depression drug
Go to article:
Ecocool
Go to article:
Moehs Iberica SL
Go to article:
Predicting drug flops with AI
Go to article:
Abiogen Pharma
Go to article:
Lauda
Go to article:
Proteomics and the promise of ‘enriching’ clinical trials
Go to article:
Lubrizol Life Sciences
Go to article:
Skycell
Go to article:
Events
Go to article:
Temptime
Go to article:
Next issue
Go to article:
Pfanstiehl Company Insight
Go to article:
Pfanstiehl